Genmab: Darzalex sales in line with expectations
Cancer drug Darzalex, which Genmab developed and is now sold by Johnson & Johnson, had a fourth quarter revenue of USD 1.645bn, which is a tad over predictions.
by marketwire, translated by daniel pedersen
Sales of Genmab-developed bone marrow cancer drug Darzalex, which has been out-licensed to Johnson & Johnson, landed on the same level as was expected by analysts in the fourth quarter of 2021, the US-based pharmaceutical giant announces in a press release, which Genmab confirms in a statement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen applies for FDA approval for Genmab drug
For subscribers
.jpg&w=384&q=75)
